- Clinical Study
- Correlation of Glypican-4 Level with Basal Active Glucagon-Like
Peptide 1 Level in Patients with Type 2 Diabetes Mellitus
-
Sang Ah Lee, Gwanpyo Koh, Suk Ju Cho, So-Yeon Yoo, Sang Ouk Chin
-
Endocrinol Metab. 2016;31(3):439-445. Published online September 26, 2016
-
DOI: https://doi.org/10.3803/EnM.2016.31.3.439
-
-
4,542
View
-
41
Download
-
8
Web of Science
-
7
Crossref
-
 Abstract
 PDF Supplementary Material PubReader
- Background
Previous studies have reported that glypican-4 (GPC4) regulates insulin
signaling by interacting with insulin receptor and through adipocyte
differentiation. However, GPC4 has not been studied with regard to its
effects on clinical factors in patients with type 2 diabetes mellitus
(T2DM). We aimed to identify factors associated with GPC4 level in T2DM. MethodsBetween January 2010 and December 2013, we selected 152 subjects with T2DM
and collected serum and plasma into tubes pretreated with aprotinin and
dipeptidyl peptidase-4 inhibitor to preserve active gastric inhibitory
polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). GPC4, active GLP-1,
active GIP, and other factors were measured in these plasma samples. We
performed a linear regression analysis to identify factors associated with
GPC4 level. ResultsThe subjects had a mean age of 58.1 years, were mildly obese (mean body mass
index [BMI], 26.1 kg/m2), had T2DM of long-duration (mean, 101.3
months), glycated hemoglobin 7.5%, low insulin secretion, and low insulin
resistance (mean homeostatic model assessment of insulin resistance
[HOMA-IR], 1.2). Their mean GPC4 was 2.0±0.2 ng/mL. In multivariate
analysis, GPC4 was independently associated with age (β=0.224,
P=0.009), and levels of active GLP-1 (β=0.171,
P=0.049) and aspartate aminotransferase (AST;
β=–0.176, P=0.043) after being adjusted for
other clinical factors. ConclusionGPC4 was independently associated with age, active GLP-1, and AST in T2DM
patients, but was not associated with HOMA-IR and BMI, which are well known
factors related to GPC4. Further study is needed to identify the mechanisms
of the association between GPC4 and basal active GLP-1 levels.
-
Citations
Citations to this article as recorded by  - How Reliable are Commercially Available Glypican4 ELISA
Kits?
Joseph P. Buhl, Antje Garten, Jürgen Kratzsch, Wieland Kiess, Melanie Penke
Experimental and Clinical Endocrinology & Diabetes.2022; 130(02): 110. CrossRef - Serum glypican-4 is associated with the 10-year clinical outcome of patients with peripheral artery disease
Axel Muendlein, Christine Heinzle, Andreas Leiherer, Kathrin Geiger, Eva Maria Brandtner, Stella Gaenger, Peter Fraunberger, Christoph H. Saely, Heinz Drexel
International Journal of Cardiology.2022; 369: 54. CrossRef - Berberine activates the β-catenin/TCF4 signaling pathway by down-regulating miR-106b to promote GLP-1 production by intestinal L cells
Jiao Wang, Li-Rui Wei, Yan-Ling Liu, Cheng-Zhi Ding, Feng Guo, Jiao Wang, Qian Qin, Feng-Jiao Huang, Ying Xin, Sheng-Nan Ma, Qiu-Ran Zhai, Shou-Jun Wang, Gui-Jun Qin
European Journal of Pharmacology.2021; 911: 174482. CrossRef - Increased Glypican-4 Levels Are Associated with Obesity in Adolescents
Huseyin Dag, Nevin Cetin Dag, Okan Dikker
Iranian Journal of Pediatrics.2019;[Epub] CrossRef - Serum glypican 4 level in obese children and its relation to degree of obesity
Chutima Leelalertlauw, Manassawee Korwutthikulrangsri, Pat Mahachoklertwattana, Suwannee Chanprasertyothin, Patcharin Khlairit, Sarunyu Pongratanakul, Preamrudee Poomthavorn
Clinical Endocrinology.2017; 87(6): 689. CrossRef - Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef - Efficacy and Safety of Single‐ or Double‐Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta‐Analysis
Xi‐Ling Yang, Mi‐Ma Duo‐Ji, Zi‐Wen Long
Journal of Cellular Biochemistry.2017; 118(12): 4536. CrossRef
|
KES
